Shin Nippon Biomedical Laboratories News and Resources

Satsuma Pharmaceuticals, Inc., a late-stage biopharmaceutical company, along with its parent company Shin Nippon Biomedical Laboratories, Ltd. (SNBL), a contract research organization has confirmed that the U.S. Food and Drug Administration (FDA) has accepted its resubmitted New Drug Application (NDA)